Home › Compare › LBPS vs EQR

LBPS vs EQR: Dividend Comparison 2026

LBPS yields 121.21% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBPS wins by $8.90M in total portfolio value
10 years
LBPS
LBPS
● Live price
121.21%
Share price
$1.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.95M
Annual income
$3,410,602.48
Full LBPS calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — LBPS vs EQR

📍 LBPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBPSEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBPS + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LBPS pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBPS
Annual income on $10K today (after 15% tax)
$10,303.03/yr
After 10yr DRIP, annual income (after tax)
$2,899,012.11/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, LBPS beats the other by $2,894,357.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBPS + EQR for your $10,000?

LBPS: 50%EQR: 50%
100% EQR50/50100% LBPS
Portfolio after 10yr
$4.50M
Annual income
$1,708,039.04/yr
Blended yield
37.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LBPS
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBPS buys
0
EQR buys
0
No recent congressional trades found for LBPS or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBPSEQR
Forward yield121.21% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$8.95M$47.8K ✓
Annual income after 10y$3,410,602.48 ✓$5,475.61
Total dividends collected$8.14M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: LBPS vs EQR ($10,000, DRIP)

YearLBPS PortfolioLBPS Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$22,821$12,121.21$11,380$679.82+$11.4K → LBPS
2$50,271$25,852.41$13,014$837.25+$37.3K → LBPS
3$107,013$53,222.70$14,961$1,036.20+$92.1K → LBPS
4$220,388$105,884.01$17,297$1,289.22+$203.1K → LBPS
5$439,612$203,797.23$20,121$1,613.15+$419.5K → LBPS
6$850,309$379,924.02$23,561$2,030.84+$826.7K → LBPS
7$1,596,614$686,783.92$27,783$2,573.54+$1.57M → LBPS
8$2,913,579$1,205,201.50$33,013$3,284.39+$2.88M → LBPS
9$5,172,959$2,055,429.68$39,547$4,223.51+$5.13M → LBPS
10$8,945,669$3,410,602.48$47,791$5,475.61+$8.90M → LBPS

LBPS vs EQR: Complete Analysis 2026

LBPS — Stock

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Full LBPS Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LBPS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBPS vs SCHDLBPS vs JEPILBPS vs OLBPS vs KOLBPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.